 Melphalan at a myeloablative dose followed by autologous stem cell transplantation remains the standard of care for transplant eligible patients with myeloma . However therapies such as new immunomodulatory drugs and proteasome inhibitors and more recently monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT . Which patients benefit from ASCT Can its use be delayed until first relapse The field is moving rapidly as novel agents lead to new patient care strategies . The place of ASCT in this changing landscape will be reviewed and reassessed .

@highlight Dramatic improvements have been made in the treatment of myeloma.
@highlight Monoclonal antibodies are improving the rate and depth of response.
@highlight New drug combinations and chimeric antigen receptor T cell therapy challenge the role of autologous stem cell transplantation in myeloma.
